_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
IART
Primary Facts
Medical Devices
Name:
-
Sector:
30.28M
Industry:
47.34
CEO:
Mr. Peter Arduini
Total Employees:
Mid Cap
Our Technological Advancement Rating
Our Rating:
0.092499794
-0.524673873
Integra Lifesciences Holdings Corporation (XNAS:IART) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
INTEGRA LIFESCIENCES HOLDINGS CORPORATION (XNAS:IART)
One Month Price Target:
Six Month Price Target :
$47.64
Likely Price in One Year's Time:
Ticker:
$49.12
Likely Trading Range Today Under (Normal Volatility)
$47.51
Price Upper limit ($) :
$50.9
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P294
This week:
$45.21
This month :
$42.58
Other Primary facts
Market Cap:
83.50M
Market Cap Classification:
3.90B
Number of Shares
IPO Date:
B
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-9.03%
$37.83
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$52.74
13.75%
$41.94
$57.22
Medium risk (<10%) entry points
Buy Call
Sell Call
$50.33
Buy Put:
Sell Put:
$37.46
$44.35
$51.29
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Devices
Sharpe Ratio:
IART, is amongst the top 40% lowest yielding stocks in terms of daily returns
Comparison:
1.51%
-1.688460883
Sharpe ratio is -168.85% lower than the industry
Average Returns/Yield of
Medical Devices
Daily returns:
1
Weekly returns:
-0.01%
Monthly returns:
-0.07%
Yearly returns:
-3.34%
Comparison of returns:
-1.217222463
Classification:
Average annual returns/yield (last 3 years) is -121.72% below industry average
Results of T-Test of Returns:
IART is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.41
Volatility (measured by Standard Deviation)
Daily Volatility:
& is -145.75% lower than the market/S&P 500 average
Weekly Volatility:
2.18%
Monthly Volatility:
4.88%
Yearly Volatility:
9.76%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
42.53%
-91.35%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -91.35% below long-term volatility
Weekly VaR:
-4.49%
Monthly VaR:
-10.05%
How Much Can the price of
Medical Devices
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Low (<25%)
Worst case (decline):
$38.85
This translates to price declining to:
-18%
This translates to price declining to:
-69.62%
Severe Crash Probability
-20.10%
What is Value at Risk (VaR)?
Risk Fundamentals
21.53%
IART is a 41.85% riskier investment compared to the market/S&P 500 & is 21.53% riskier than Nasdaq (IXIC)
IART is a 41.85% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Devices
1.120
Expected beta in 1 year's time:
0.571
Expected beta in 3 year's time:
0.666
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--1.12
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is 5.14% above industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.613
-0.013
Average Industry Beta:
Beta is -1.33% lower than peers
0.051350821
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is -9.60% below industry mean WACC
6.33%
Alpha provided | Alpha Analysis
Alpha provided:
0.941
-3.881
-9.010
Analysis of Cost of Capital of
Medical Devices
Equity cost of capital:
Alpha is -901% below the market average
0.036
Unlevered (without debt) cost of capital:
Equity cost of capital is 3.59% above industry mean WACC
Before-tax cost of debt:
5.93%
After-tax cost of debt:
2.98%
Overall debt rating:
2.35%
Weighted average cost of capital (WACC):
2.98%
-9.60%
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is -72.76% below the industry mean
-98.81%
EPS:
One Hundred Fifty-Two Million Nine Hundred Sixty-Eight Thousand Four Hundred Dollars
Expected Annual growth rate of EPS (3Y):
Price to free cash flow ratio is -69.30% lower than the industry
333.27%
Free cash flow (FCF) per share:
Price to book ratio is -71.45% below the industry mean
Growth rate in R&D investment/expenditure is -15543.41% lower than the industry
-
Debt per share
Debt repayment rate in last quarter: 0.73%
EBITDA per share
Each employee generates 1286% more EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Devices
P/E Ratio:
Sustainable growth rate is 6.33% above industry average
P/E Ratio of Competitors/Peers:
24.14
-0.900881349
448.1236955
-0.894359525
$3.29
-
P/S (Price to Sales ratio):
$18.67
-0.727599958
P/B (Price to book value ratio):
Price to sales ratio is -72.76% below the industry mean
-
-0.692982025
Net income growth rate (3Y):
Annual revenue growth rate is -98.81% below industry average
82.50%
Dividend Analysis
Net income growth rate is 82.50% higher than the average industry net income growth rate
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
-
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
76.89%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 6.2 years
Debt to assets ratio:
33.82%
Net debt to assets ratio:
98.42%
11.74%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is 11.74% above industry average
-0.50
Looking forward:
Debt growth rate:
1.8x
-117.75%
0.73%
Analysis of Key Statistics
Correlation of price movement with the market:
13.35761216
Statistical significance of correlation:
-0.38%
Average Correlation of the industry with the market:
0.455
-2.73%
R Squared (percentage of price movement explained by movement of the market):
0.455
Correlation of price movement with Nasdaq (^IXIC):
0.207
Covariance of price movement with the market:
0
Kurtosis
0
4.185
Skewness of returns:
Returns have moderate fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
0.380
Fundamental Analysis & Dupont Analysis of
Medical Devices
Gross Profit Margin Ratio:
964.46M
Operating Profit Margin Ratio:
Net profit margin is -158.82% lower than the industry
-179.90%
Net Profit Margin Ratio:
964.46M
Effective Tax Rate:
4.02%
-0.706176514
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is -226.49% lower than the industry
-198.88%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -179.90% lower than the industry
-226.49%
Financial Leverage:
Interest coverage ratio is -49.71% less than industry average
Current Ratio:
Return on equity (ROE) is -198.88% lower than the industry
-0.477878503
Cash Conversion Cycle (days):
$19.04
0.163114229
Current ratio is -47.79% below industry average
Stock based compensation to net income ratio:
-
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is 16.31% above industry average
0.088568309
EBITDA generated per employee:
Each employee generates 9% more revenue than industry average revenue per employee
12.86095458
Profit generated per employee:
$3.95
-239%
Free cash flow (FCF) generated per employee:
Each employee generates -239% less net income/profit than industry average revenue per employee
-1.560935393
Assets/Capital per employee
Each employee generates -156% less free cash flow than industry average revenue per employee
-1.560935393
Research & Development (R&D) Analysis
20.25%
-155.4340772
Competitors/Peer firms of
Medical Devices
$107.92
ARENA PHARMACEUTICALS, INC. (XNAS:ARNA)
CureVac NV (XNAS:CVAC)
BLUEPRINT MEDICINES CORPORATION (XNAS:BPMC)
ZAI LAB LIMITED (XNAS:ZLAB)
HALOZYME THERAPEUTICS, INC. (XNAS:HALO)
ROIVANT SCIENCES LTD. (XNAS:ROIV)
EXELIXIS, INC. (XNAS:EXEL)
SHOCKWAVE MEDICAL, INC. (XNAS:SWAV)
Current Analyst Ratings
$1.84
Strong buy�21%
Buy�17%
Hold�25%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
1.56B
594.55M
247%
94.76M
-
640.74M
-
16.28M
1.35B
6.37M
49.12M
93.68M
85%
30.13M
- 25966.00K
48%
30.13M
Statement of Cash Flow
Date:
Period:
32.90M
Differed Income Tax :
29.72M
Stock Based Compensation :
3.54M
Change in Working Capital :
6.29M
Accounts Receivables:
- 29770.00K
Other Working Capital:
- 9754.00K
Other Non-Cash Items:
-
Net Cash Provided by Operating Activities:
1.65M
Investments in PP&E:
44.34M
Net Acquisitions:
- 9325.00K
Purchases of Investments:
-
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
3/31/2022
2022
Q1
407.09M
-
407.09M
234.01M
328.01M
96.95M
1.07B
390.85M
1.01B
1.12B
-
54.68M
29.51M
2.61B
-
3.67B
88.37M
59.30M
-
5.34M
162.82M
315.83M
1.59B
94.60M
1.74B
-
2.06B
900.00K
731.47M
- 21025.0K
Value
751.78M
903.85M
1.62B
3.67B
-
1.65B
-
-
- 4742.00K
- 14067.00K
- 11750.00K
-
- 125000.00K
-
3.29M
- 133465.00K
- 3168.00K
- 106356.00K
407.09M
513.45M
44.34M
- 14067.00K
Our Proprietary Portfolio Rating
Our Rating:
64.96373232
Price Forecast/Expected Price in Next 5 Years of
Medical Devices
2023
2024
2025
2026
2027
80.74071452
$51.15
$86.81
$93.35
$100.37